Market for Lymphoma - The two main groups of Lymphoma in humans are Hodgkin's disease (characterized by the growth of Reed-Sternberg cells) and the non-Hodgkin's lymphoma (NHL).DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c38331) has announced the addition of Lymphoma - A Therapeutic & Competitive Insight to their offering. Lymphoma is a broad term encompassing a variety of cancers of the lymphatic system lymphatic system (lĭmfăt`ĭk), network of vessels carrying lymph, or tissue-cleansing fluid, from the tissues into the veins of the circulatory system. . The two main groups of lymphoma in humans are Hodgkin's disease Hodgkin's disease, a type of cancer of the lymphatic system. First identified in 1832 in England by Thomas Hodgkin, it is a type of malignant lymphoma. Incidence peaks in young adults and the elderly. (characterized by the growth of Reed-Sternberg cells) and the non-Hodgkin's lymphoma non-Hodg·kin's lymphoma n. Any of various malignant lymphomas characterized by the absence of Reed-Sternberg cells. Non-Hodgkin's lymphoma (NHL NHL Non-Hodgkin's lymphoma, see there ). The world prevalence is approximately 650,000 cases, of which 300,000 are low grade and 350,000 are aggressive. The lymphoma market is a complex topic and several pitfalls await actors not well prepared. This report will guide through this field and bring structure and knowledge enable our customers to analyze opportunities. This report will help to answer questions on the subject of additional lymphoma treatments beyond Rituxan. Research and analysis highlights At the American Society of Clinical Oncology American Society of Clinical Oncology, or ASCO, is an organization that represents all clinical oncologists. Every year, ASCO holds a large symposium where physicians and researchers meet to convey and discuss research and ideas. 2005 meeting new investigations showed that freedom from treatment failure was significantly better for patients with Hodgkin's disease undergoing transplantation compared to non-transplant salvage, regardless of whether they relapse early or late following primary chemotherapy. Rituximab has been heavily investigated in a variety of treatment regimes. Published trial data show an increase in response rates when rituximab is combined with current chemotherapy regimens Chemotherapy regimens are often identified with acronyms, identifying the agents used in combination. Unfortunately, the letters used are not consistent across regimens, and in some cases (for example, "BEACOPP") the same letter is used to represent two different treatments. in both the first- and second- line settings. In addition, rituximab show significant off-label usage. Already today it is clear that rituximab has generated substantial revenues for the companies involved in its development. A collection of emerging facts suggest that numerous of the new targeted therapies are agents that cannot just be added into treatment regimens with conventional drugs. A few of them might have isolated properties on certain biologic targets that may require to be modulated mod·u·late v. mod·u·lat·ed, mod·u·lat·ing, mod·u·lates v.tr. 1. To adjust or adapt to a certain proportion; regulate or temper. 2. in particular ways before or after cytotoxic cy·to·tox·ic adj. Of, relating to, or producing a toxic effect on cells. cy  to·tox·ic chemotherapy. Among the emerging therapeutic strategies, passive and active immunotherapies have clearly continued to be leading strategies. Small molecule apoptotic inducers and kinase inhibitors are as well in the forefront. Scope of this report Thorough examination of status and impact of several novel drugs in development Discussion of the challenges in current treatment strategies. Company profiles and their anticancer pipeline of most companies in the field Key reasons to read this report Explore the strengths and weaknesses associated with compounds in clinical development. Scientific rationale for most novel therapeutics in lymphoma R&D, and the results of clinical trials to date. Gain insight into the current challenges and commercial opportunities associated with lymphoma therapy Some of the drugs included in this analysis: Aldesleukin , Apolizumab, Arsenic trioxide arsenic trioxide Warning - Hazardous drug! Trisenox Pharmacologic class: Nonmetallic element, white arsenic Therapeutic class: Antineoplastic , Bevacizumab, BiovaxID, Bortezomib, CMC-544 , Enzastaurin , Epratuzumab, FavId , Flavopiridol, Genasense , IDEC-114 , Marqibo, MyVax, Nelarabine , Pixantrone, SGN-30, SGN-40, Temsirolimus, Zanolimumab. Some of the companies included in this analysis Accentia BioPharmaceuticals, Biogen, Cell Therapeutics, Cephalon Ceph´a`lon n. 1. (Zool.) The head. , Chiron (now Novartis) Corporation, Eli Lilly Eli Lilly can refer to:
Companies Mentioned Include: - Accentia BioPharmaceuticals - Biogen - Cell Therapeutics - Cephalon - Chiron (now Novartis) Corporation - Eli Lilly - Favrille - Genentech - Genitope - Genmab - Genta - GlaxoSmithKline - Immunomedics - Inex Pharmaceuticals - Millennium Pharmaceuticals - Protein Design Labs - Roche - Sanofi-Aventis - Seattle Genetics - Wyeth Contents are as follows:- Lymphoma A Therapeutic & Competitive Insight 1Executive Summary 2Cancer Highlights 3Methodology 4Table of Contents 5Introduction 6Current Treatment Strategies 7Progress in Current Treatment Strategies 8Key Therapeutic Strategies 9Competitive Landscape in Drug Development: The Late Stage Pipeline 10 Current Drug Development: The Early Stage Pipeline 11 Disclaimer 12 Appendix 1: Selected Companies - Anticancer Pipelines Company & Drug Index List of Boxes List of Figures List of Tables For more information visit http://www.researchandmarkets.com/reports/c38331 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion